Commerzbank set a €100.00 ($116.28) target price on Merck KGaA (FRA:MRK) in a research note released on Wednesday, October 17th. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other brokerages have also commented on MRK. Berenberg Bank set a €104.00 ($120.93) price objective on shares of Merck KGaA and gave the stock a buy rating in a report on Thursday, August 9th. Goldman Sachs Group set a €92.00 ($106.98) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, September 24th. Nord/LB set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Thursday, August 9th. Warburg Research set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, July 3rd. Finally, Deutsche Bank set a €91.00 ($105.81) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, August 13th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. Merck KGaA has an average rating of Hold and a consensus target price of €98.16 ($114.14).
Merck KGaA stock traded down €0.38 ($0.44) during trading on Wednesday, reaching €94.86 ($110.30). 483,184 shares of the company’s stock were exchanged. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: Beta
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.